Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing Proposed Standard and the E-Test with the NCCLS Broth Microdilution Method for Voriconazole and Caspofungin Susceptibility Testing of Yeast Species
- 1 October 2002
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (10) , 3841-3844
- https://doi.org/10.1128/jcm.40.10.3841-3844.2002
Abstract
The proposed standard of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST) and the E-test procedures were compared with the NCCLS reference broth microdilution method for voriconazole and caspofungin susceptibility testing of 102 clinical Candida species and Saccharomyces cerevisiae isolates. The voriconazole MIC at which 50% of strains were inhibited (MIC 50 ) was ≤0.125 mg/liter for all yeast species except for Candida glabrata and Candida krusei , which yielded MIC 50 values of 0.25 to 1 mg/liter depending on the method. Caspofungin exhibited in vitro activity (MIC 50 of ≤0.125 to 2 mg/liter) against all yeast species except for Candida guilliermondii . The agreements between MICs within ±2 dilutions obtained by the NCCLS method and the EUCAST standard were 97% for voriconazole and 96% for caspofungin. Intraclass correlation coefficients were statistically significant ( P < 0.05). The agreements between voriconazole MICs provided by the E-test and the NCCLS and between the E-test and the AFST-EUCAST method were 100 and 90%, respectively. Because of lower caspofungin MICs provided by the E-test, the agreement was slightly poorer with the NCCLS method (89%) than with the AFST-EUCAST procedure (94%). Both the EUCAST and the E-test procedures can be reliable techniques for susceptibility testing of yeasts to voriconazole and caspofungin.Keywords
This publication has 13 references indexed in Scilit:
- Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive AspergillosisClinical Infectious Diseases, 2002
- Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent FeverNew England Journal of Medicine, 2002
- Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of Candida SpeciesJournal of Clinical Microbiology, 2001
- Trends in Antifungal Susceptibility among Swedish Candida Species Bloodstream Isolates from 1994 to 1998: Comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A Reference MethodJournal of Clinical Microbiology, 2001
- Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infectionsExpert Opinion on Investigational Drugs, 2001
- Influence of Glucose Supplementation and Inoculum Size on Growth Kinetics and Antifungal Susceptibility Testing of Candida sppJournal of Clinical Microbiology, 2001
- CaspofunginDrugs, 2001
- In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies.Journal of Antimicrobial Chemotherapy, 2000
- Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.Journal of Antimicrobial Chemotherapy, 1998
- Comparison of broth macrodilution, broth microdilution and E‐test susceptibility tests of Cryptococcus neoformans for fluconazoleMycoses, 1997